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ABSTRACT
Naturally occurring extracellular vesicles (EVs) play essential roles in intracellular 
communication and delivery of bioactive molecules. Therefore it has been suggested 
that EVs could be used for delivery of therapeutics. However, to date the therapeutic 
application of EVs has been limited by number of factors, including limited yield and 
full understanding of their biological activities. To address these issues, we analyzed 
the morphology, molecular composition, fusion capacity and biological activity of 
Cytochalasin B-induced membrane vesicles (CIMVs). The size of these vesicles was 
comparable to that of naturally occurring EVs. In addition, we have shown that 
CIMVs from human SH-SY5Y cells contain elevated levels of VEGF as compared to 
the parental cells, and stimulate angiogenesis in vitro and in vivo.
INTRODUCTION
Cell therapy has been proven as an effective method 
for injury treatment [1-4]. Although considerable advances 
were made, current understanding of the mechanisms of 
transplanted cell therapeutic effects is incomplete. It is 
known that the tissue repair achieved is independent of 
transplanted cell-engraftment [5-6] and it can be achieved 
by injection of conditioned media derived from stem cell 
cultures [7-8] suggesting the therapeutic effect is paracrine 
and associated with the release of soluble factors. 
According to the paracrine hypothesis, transplanted cells 
secrete biologically active factors including cytokines 
and growth factors into extracellular space activating 
resident cells and supporting tissue growth and repair 
[9-10]. More recent evidence also supports a paracrine 
role for extracellular vesicles (EVs) [11]. EV are important 
vehicles carrying proteins, mRNA, miRNAs and siRNA 
and provide a mechanism for cell crosstalk within tissues. 
Therefore, EVs could have great therapeutic potential 
as vehicles to deliver biologically active molecules. The 
therapeutic capacity of EVs was shown using models of 
a kidney injury [12], heart [13-14], liver [15] and nervous 
tissue injury [16].
In the last decade, technological advances have 
improved the yield and quality of isolated EVs [17-19]. 
Pick and colleagues [20] demonstrated that active 
agitation of Cytochalasin B-treated cells stimulated the 
production of membrane vesicles [20]. The membrane 
vesicles produced in this way retain normal cellular 
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signaling capacities [20]. Mao and colleagues used the 
Cytochalasin B induced membrane vesicles as vectors 
for drug and nanoparticles delivery [21]. However the 
biological activities of membrane vesicles obtained from 
Cytochalasin B-treated cells have not been evaluated.
In this study, human neuroblastoma SH-SY5Y 
cells [22] were chosen as a source of CIMV due to their 
well-established angiogenic properties. It is known 
that neuroblastoma is a highly vascular solid tumor 
[23]. Previously we have shown that SH-SY5Y cells 
induce formation of capillary-like structures by human 
mesenchymal stem cells [24]. Therefore, in the current 
study we sought to determine whether Cytochalasin 
B induced membrane vesicles (CIMVs) derived from 
SH-SY5Y bone marrow neuroblastoma cells could 
promote angiogenesis. To this end we examined the 
morphology, molecular composition, fusion capacity and 
biological activity of membrane vesicles generated using 
Cytochalasin B-treated SH-SY5Y cells. We have found 
that CIMVs maintain angiogenic properties of the parental 
cells in vitro and in vivo.
RESULTS
Characterization of CIMVs
Cytochalasin B targets actin cytoskeleton [25], 
therefore we first sought to determine the effect of 
Cytochalasin B treatment on actin fibers in SH-SY5Y cells 
as well as in CIMVs. Continuous actin microfilaments are 
found in untreated control SH-SY5Y cells (Figure 1). In 
contrast, in Cytochalasin B-treated SH-SY5Y cells actin 
microfilaments were disrupted and appeared as a sub-
membrane “islands” (Figure 1). Confocal microscopy 
revealed actin cytoskeleton fragments in CIMVs (Figure 1).
Next, we investigated the structure and size of SH-
SY5Y derived CIMVs using transmission and scanning 
electron microscopy. We found that CIMVs had a round-
shaped structure with a diameter varying from 80 to 1790 
nm. It should be noted that the majority of CIMVs (96%) 
had a diameter of 100-1000 nm (Figure 2C) which is 
within the range of naturally occurring EVs.
Interaction of CIMVs with recipient SH-SY5Y 
cells
The cytoplasmic membrane of CIMVs and recipient 
SH-SY5Y cells were differentially labeled with DiD 
(red fluorescent dye) and DiO (green fluorescent dye), 
respectively. DiD and DiO dyes have non-overlapping 
excitation/emission spectrum (DiD – 644/665 nm; DiO 
– 484/501 nm) and do not transfer between cytoplasmic 
membranes of neighboring cells [26]. CIMVs were 
incubated with the recipient SH-SY5Y cells and the surface 
and inner content of recipient SH-SY5Y cells were analyzed 
to determine the presence of the CIMVs membrane 
component. FACS analysis revealed that the majority of cells 
(95.88%) had DiO and DiD dual fluorescence (Figure 3G). 
Round structures with red fluorescence (DiD positive) were 
detected on SH-SY5Y surface (Figure 3A-3C). Round 
structures with dual red and green fluorescence were 
detected within the cytoplasm of recipient SH-SY5Y 
(Figure 3D-3F, 3H). This data suggests that CIMVs merge 
with SH-SY5Y membranes and engage in the endosome 
trafficking pathway (Figure 3G).
CIMVs exhibit angiogenic activity in vitro
Previously we have shown that SH-SY5Y cells 
stimulate mesenchymal stem cell (MSC) formation 
of capillary-like tubes in matrigel [24]. Therefore we 
sought to compare whether SH-SY5Y derived CIMVs 
retain this pro-angiogenic property of the parental SH-
SY5Y cells. SH-SY5Y cells were mitotically inactivated 
using mitomycin C to eliminate the changes in secreted 
growth factors concentration introduced by active cell 
proliferation.
HUVECs capillary-like tube formation in matrigel 
was examined in vitro to determine the pro-angiogenic 
properties of CIMVs. HUVECs were pre-stained with 
CFDA-SE (eBioscience, USA) and co-cultured with 
CIMVs or mitotically inactivated SH-SY5Y cells for 
16 hours before analysis of the capillary-like network 
(Figure 4A). The mean number of HUVECs capillary-
like network branch points was calculated using Image 
J software. The mean number of capillary-like network 
branch points in the negative control group (HUVECs 
cultured in MCDB131 medium with 1% FBS) was 
5.3 ± 3.8 (Figure 4B). As expected, HUVECs cultured 
with SH-SY5Y cells showed a significantly increased 
number of capillary-like structures (43.5 ± 3.5; p<0.01) 
as compared to negative control. Furthermore, co-
culture of HUVECs with mitotically inactivated SH-
SY5Y cells also induced a significantly increased 
number of capillary-like structures (34.7 ± 1.15; p<0.01). 
Consistent with our hypothesis that CIMVs retain 
the pro-angiogenic activity of the parental SH-SY5Y 
cells, CIMVs were shown to also induced a significant 
increase in capillary-like structures as compared to the 
negative control group (41.3 ± 8.5;p<0.01) (Figure 4B). 
Indeed, under the conditions employed we found that 
CIMVs induced comparable HUVECs capillary-like 
structures as achieved by mitotically competent SH-SY5Y 
in vitro. Furthermore, CIMV induced angiogenesis was not 
associated with changes in HUVECs viability (Figure 3, 
Supplementary Data).
Endothelial cell proliferation is regulated primarily 
by ligands for receptor tyrosine kinases (RTKs) [23]. 
Therefore we sought to determine whether the angiogenic 
activity of CIMVs is associated with VEGF. We found 
~1.5 fold higher level of VEGF in SH-SY5Y-derived 
CIMVs as compared to SH-SY5Y cells (Figure 4C).
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CIMVs stimulate angiogenesis in vivo
Given the increased capillary-like structure 
formation by HUVECs incubated with CIMVs in vitro, 
we next examined the pro-angiogenesis activity of CIMV 
in vivo using the matrigel plug angiogenesis assay in rat 
model. CIMVs and cells were first stained with DiO, 
then matrigel solutions (200 μl) containing either CIMVs 
or native or mitotically inactivated SH-SY5Y cells as 
controls were prepared and injected subcutaneously into 
Figure 1: Comparison of the actin cytoskeleton structure in native and cytochalasin B treated cells and presence of 
actin filaments in CIMVs. SH-SY5Y cells were pre-stained with the cytoplasmic membrane dye DiD, then native cell (A-C), cells after 
30 min incubation with cytochalasin B (D-F), or CIMVs (G-I) were fixed and stained with Phalloidin-Alexa488. Micrographs indicate that 
cytochalasin B induces actin cytoskeleton disorganization and as a consequence the loss of cells form. The actin cytoskeleton fragments 
which were formed under the effect of cytochalasin B are part of the CIMVs (G-I).
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rat abdominal flanks. Histological examination of matrigel 
implants was conducted 8 days later. Native, mitotically 
inactivated SH-SY5Y cells and CIMVs were detected by 
confocal microscopy in the matrigel implants 8 days after 
injection (Figure 5D, 5F, 5H). Also, newly developed 
blood capillaries were observed in matrigel containing 
native, mitotically inactivated SH-SY5Y cells and CIMVs 
(Figure 5C, 5E, 5G). The number of blood vessels in control 
matrigel (without cells or CIMVs) was 0.065±0.04 cap/
mm2. More blood vessels were found in matrigel containing 
native SH-SY5Y cells, with an average capillary density 23-
fold higher (1.5±0.23 cap/mm2; p<0.01) than that in control 
(Figure 5I). Similar to native cells, the number of the new 
capillaries was 16.6 fold higher in matrigel containing 
mitotically inactivated SH-SY5Y cells (1.08±0.1 cap/mm2; 
p<0.01) than that in control. Finally, matrigel implants 
containing CIMVs achieved 12.7 fold more capillary 
density (0.83±0.02 cap/mm2; p<0.01) as compared to 
untreated control. We conclude that the SH-SY5Y derived 
CIMVs retain the pro-angiogenic properties of the parental 
Figure 2: The structure, morphology and size distribution of CIMVs. Transmission electron microscopy (A) and scanning 
electron microscopy (B) was used to analyze the biophysical properties of SH-SY5Y properties of CIMVs. (C) Size distribution of CIMVs 
SH-SY5Y. For statistical analysis, at least six electron microscope images were analyzed from three independent experiments.
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cells. Interestingly, the angiogenic property of CIMVs was 
lower than that of SH-SY5Y parental cells, but closely 
resembling that of mitotically inactive cells. Although 
this may indicate that SH-SY5Y retains additional pro-
angiogenic activity as compared to CIMVs, CIMVs also 
induced a statistically significant increase in angiogenesis 
as compared to control. As outlined later, the therapeutic use 
of CIMVs, but not native cells, is mechanistically feasible.
Figure 3: Interaction of CIMVs with recipient cells. Fluorescent microscopy Z-stack (A-F,H) and flow cytometry analysis (G) of 
SH-SY5Y recipient cells 24h after 10 μg/ml CIMVs application were carried out. Recipient cells were pre-labeled with DiO cytoplasmic 
membrane dye and CIMVs were pre-labeled with DiD dye. Cells surface (A-C) and cells inner content (D-F,H) were analyzed for the 
presence of CIMVs membrane component.
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DISCUSSION
EVs are important vehicles carrying biologically 
active molecules providing cell cross talk within the tissue 
[27]. Recently there has been significant interest in the 
potential application of EVs as tools for cell-free delivery 
of therapeutics as unlike parental cells, it is believed there 
is no risk of tumor formation [28]. However, to date the 
yield of the naturally occurring EVs has been too low and 
is insufficient for therapeutic applications. Therefore, the 
Figure 4: Evaluation of in vitro pro-angiogenic potential of mitotically inactivated cells and CIMVs SH-SY5Y. (A) 
Fluorescence micrographs of HUVEC culture after 16 hours of incubation with native/ mitotically inactivated SH-SY5Y cells or CIMVs. 
(B) Quantitation of the capillary-like structure branch points number formed by HUVECs after 16 hours of co-culture with native/ 
mitotically inactivated SH-SY5Y cells or CIMVs. The data represents mean {plus minus} SD. For statistical analysis six well of 96-well 
plate were analyzed per experimental group. (C) Representative western blots showing VEGF and β-actin in native/ mitotically inactivated 
SH-SY5Y cells or CIMVs.
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Figure 5: CIMVs stimulate angiogenesis in vivo. Representative images of matrigel plugs with native (C, D), mitotically inactivated 
(E, F) SH-SY5Y cells or CIMVs (G, H) 8 days after subcutaneous injection in Rattus norvegicus (6 animals per experimental group). 
Hematoxylin/eosin staining and fluorescence micrographs are shown. Mg - Matrigel, Cap - fibrous capsule. Arrows mark the position of 
the sprouting blood capillaries. (I) Quantitation of the capillary density in matrigel plugs. The data represents mean {plus minus} SD. For 
statistical analysis, fifteen hematoxylin and eosin stained slides per animal were analyzed.
AQ:1
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development of new methods to generate EVs has been an 
area of active research. The use of cytochalasin B is now a 
well-established approach to generate sufficient quantities 
of EVs for therapeutic development [20]. However, it 
remained unclear whether CIMVs retain cell regulatory 
capacity similar to those of naturally occurring EVs.
Studies of the molecular mechanisms regulating 
extracellular vesicles formation, revealed that budding 
of microvesicles requires local actin cytoskeleton 
disorganization by the Ca2+-dependent protease, calpain, 
where digested actin microfilament fragments become 
captured within the microvesicles [29-30]. Since 
cytochalasin B mechanisms of action are similar to those 
of calpain, the presence of actin microfilaments within 
the CIMVs was investigated. Here we found that actin 
molecules are captured in CIMVs. Furthermore, we show 
that CMIVs were ~100-1000 nm in diameter, which is 
comparable with naturally occurring EVs [31-35].
Naturally occurring EVs can acquire and transport 
biologically active molecules. Also, EVs are able to fuse 
directly with the cytoplasmic membrane of recipient cells 
and be captured by endocytosis [36]. However whether the 
membrane fusion capacity and mechanisms of intracellular 
transport were retained by CIMVs was unknown. Here 
for the first time we have shown that CIMVs can fuse 
with the recipient cell membrane. Also, we found that 
CIMVs, like naturally occurring EVs, can be transported 
via endocytosis. This data suggests that CIMVs may have 
similar bio-physical properties, closely resembling that 
of natural microvesicles, and thus are likely suitable as 
vectors for delivery of bioactive molecules.
Naturally occurring EVs can deliver biologically 
active substances to recipient cells, and thereby regulate 
cell growth and proliferation [37-38]. Therefore, we 
investigated the effect of CIMVs on HUVECs capillary-
like structures formation in vitro. Our data, for the first 
time indicates that CIMVs can induce the angiogenesis, 
similar to that previously described for the parental cells 
[24]. We believe that VEGF could, in part, explain the pro-
angiogenic properties of CIMVs.
The pro-angiogenic potential of the SH-SY5Y 
neuroblastoma cells derived CIMVs was also confirmed 
using an in vivo model. Tumor cells secrete various 
cytokines and chemokines attracting endothelial cells 
[39] and thereby stimulate angiogenesis. Subcutaneously 
injected in matrigel cells or CIMVs of SH-SY5Y 
induced the blood capillary sprouting by activation pro-
inflammatory and pro-angiogenic pathways [39]. Although 
the angiogenic activity of native SH-SY5Y cells was 
1.8 times higher than CIMVs, it was still comparable 
to that of mitotically inactive cells. We believe that the 
high angiogenic activity of SH-SY5Y cells was due to 
the ability of these cells to proliferate, thus continuously 
increasing the number of tumor cells releasing growth 
factors. On the contrary, CIMVs and mitomycin C treated 
cells fail to proliferate, thus although they able to secrete 
bioactive molecules, the amount of cytokines produced 
remains unchanged. The potential clinical advantages of 
this feature of CIMVs in terms of controlling therapeutic 
concentrations and minimizing off-target effects are clear.
In conclusion, we demonstrated that cytochalasin 
B-induced SH-SY5Y-derived membrane vesicles retain 
the properties of the donor cells, as they can stimulate 
angiogenesis in vitro and in vivo. Unlike the naturally 
occurring EVs, CIMVs can be produced in large quantity 
and be scaled to an industrial production level. This makes 
the CIMVs derived from primary cells (mesenchymal 
stem cells, endothelial cells, endothelial progenitor cells 
etc.) an attractive therapeutic approach to trigger the 
angiogenesis in clinical case of limb ischemia, diabetes-
caused ischemic cardiovascular disease, ischemic stroke, 
myocardial infarction [40-42]. We propose that the CIMVs 




SH-SY5Y cells (ATCC® CRL-2266, American 
Type Culture Collection, Manassas, VA) were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM; 
PanEco, Russia) with 10% fetal bovine serum (FBS; GE 
Healthcare, USA) and 2mM L-glutamine (PanEco, Russia) 
at 37°С with 5% CO2. Human umbilical vein endothelial 
cells (HUVECs) were isolated as described previously 
[43]. Experiments using human samples were reviewed 
and approved by the local Ethical Committee of Kazan 
(Volga region) Federal University based on article 20 of 
the Federal Legislation on “Health Protection of Citizens 
of the Russian Federation” № 323-FL, 21.11.2011. 
Informed consent was obtained from all patients for the 
use of specimens in research and the Helsinki Declaration 
observed. Briefly, the umbilical cord was washed with 
Hanks’ solution (PanEco, Russia) containing 100 I.U./mL 
penicillin, 100 μg/mL streptomycin (PanEco, Russia). 
Then, 1 cm of tissue was removed from each end of the 
cord. A catheter (Apexmed International, Netherlands) 
was inserted into the umbilical vein, the vein perfused 
with Hanks’ solution containing antibiotics. Umbilical 
vein endothelial cells were then dissociated by incubating 
with trypsin-EDTA (0.25%) solution (Life Technologies, 
USA) for 20 minutes at 37°С. Cells were retrieved by 
centrifugation (1500 rpm for 10 min), resuspended in 
HUVEC culture medium and incubated at 37°C in a 
humidified atmosphere containing 5% CO2. HUVECs 
phenotype was confirmed by flow cytometry (CD31+, 
CD105+, CD146+, CD144+, CD45-, CD14-). HUVECs 
were maintained in MCDB131 medium (Sigma-Aldrich, 
USA) with 20% FBS (GE Healthcare, USA) supplemented 
with non-essential amino acids (Life Technologies, USA), 
10 ng/ml FGF2 (Sigma-Aldrich, USA), 10 ng/ml VEGF 
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(Sigma-Aldrich, USA), 10 ng/ml insulin-like growth 
factor (Sigma-Aldrich, USA), 50 ng/ml endothelial cell 
growth supplement (Sigma-Aldrich, USA) and 10 ug/ml 
heparin (Sigma-Aldrich, USA).
CIMVs production
CIMVs were prepared as described by Pick et al. 
[20], with modifications. Briefly, SH-SY5Y cells were 
washed twice with PBS, and incubated in DMEM 
containing 10 μg/ml of Cytochalasin B (Sigma-Aldrich, 
USA) for 30 min (37°C, 5% CO2). At the end of 
incubation, the cell suspension was vortexed vigorously 
for 30 sec and pelleted (100 g for 10 min). The supernatant 
was subject to two subsequent centrifugation steps (100 
g for 20 min and 2000 g for 25 min). The resulting pellet 
contained CIMVs.
Actin microfilaments and cytoplasmic membrane 
staining
SH-SY5Y cells and CIMVs were fixed (10% 
formalin for 15 min), washed twice with PBS and 
permeabilized using 0.1% Tween 20 for 15 min. Phalloidin 
conjugated with Alexa 488 (SantaCruz, USA) was added 
for 15 min to visualize actin. Nuclei were stained with 
Hoechst 33342 (SantaCruz, USA) for 10 min. Lipophilic 
dyes DiD and DiO (Life Technologies, USA) were used to 
visualize cell membranes. Cell suspension (1x106 cells/ml) 
was incubated with 5μM of DiO or DiD dyes for 15 min 
(37°C, 5% CO2) and washed (3x) with complete medium 
(DMEM with 10% FBS, 2mM L-glutamine). Cells were 
analyzed by confocal laser scanning microscopy (Carl 
Zeiss LSM 780, Germany) and flow cytometry (BD FACS 
Aria III, USA).
Mitotic inactivation of SH-SY5Y cells
SH-SY5Y cells were treated with 10 μg/ml mitomycin 
C (Sigma, USA) for 1-4 hours (37°C, 5% CO2). Cells were 
washed (PBS, 3 times) and cultured in a complete culture 
media (DMEM with 10% FBS, 2mM L-glutamine). Cell 
proliferation was accessed using xCELLigence Real-Time 
Cell Analyzer (ACEA BIO, USA).
Western blot analysis
SH-SY5Y cells and CIMVs were lysed in a RIPA 
lysis buffer (50mM Tris-HCl pH 7.4, 1% Triton X-100, 
0.5% Na-deoxycholate, 0.1% SDS, 150mM NaCl, 
2mM EDTA, 1mM PMSF). Protein concentration was 
determined by bicinchoninic acid (BCA) protein assay 
(Thermo Scientific, USA). Samples (40μg) were separated 
in 12% SDS-PAGE under denaturing conditions and then 
transferred to polyvinylidene fluoride (PVDF) membrane. 
The membrane was blocked in 5% non-fat dry milk-
containing PBS-T (PBS + 0,1% Tween) solution. Proteins 
were probed using primary antibodies against VEGF 
(1:1000; SantaCruz Biotech, USA) and β-actin (1:100; 
GenScript, USA) followed by secondary antibodies 
(1:5000; GenScript, USA) conjugated with horseradish 
peroxidase. Protein bands were visualized by ECL reagent 
(Reagent A: 1.25mM Luminol in 0.1M Tris-HCl pH 8.5; 
reagent B: 68mM p-Coumaric acid in DMSO; reagent C: 
30% hydrogen peroxide) and detected on a ChemiDoc 
Imaging System by Image Lab software (Bio-Rad, USA). 
Densitometric analysis, relative to total protein, was 
performed using Image J software.
Transmission and scanning electron microscopy
CIMVs were fixed (2.5% glutaraldehyde, 24 hours) 
and incubated in 1% osmium tetroxide for 1 hour. CIMVs 
were dehydrated using graded ethanol series, followed by 
acetone, oxypropylene and epoxy resin embedment. The 
ultrathin sections were cut using Leica EM ultramicrotome 
(Leica, USA), mounted on copper grid (Sigma, USA) and 
contrasted with uranyl acetate and lead citrate (Himmed, 
Russia). Sections were examined using Jeol SX 1200 
electron microscope (Jeol, Japan). For SEM, CIMVs 
were fixed (10% formalin for 15 min), dehydrated using 
graded alcohol series and dried at 37°C. Prior to imaging, 
samples were sputter coated with gold/palladium in a 
Quorum T150ES sputter coater (Quorum Technologies 
Ltd, United Kingdom). Slides were analyzed using Merlin 
(CarlZeiss, Germany) field emission scanning electron 
microscope. For size determination, CIMVs were obtained 
in three independent experiments and at least six electron 
microscope images were done in each experiment for 
subsequent statistical analysis.
In vitro assessment of capillary-like structure 
formation by HUVECs
HUVECs (2×104 cells) were seeded in tissue culture 
wells pre-coated with Matrigel Growth Factor Reduced 
Basement Membrane Matrix (Becton Dickinson, USA). 
CIMVs were added to the HUVECs monolayer at a 
concentration equivalent to 2×104 SH-SY5Y cells based 
on total protein concentration. HUVECs maintained in 
MCDB131 media supplemented with 1% FBS was used as 
a negative control. HUVECs and CIMVs were incubated 
for 16 hours (37°C, 5% CO2) and used to analyze by 
AxioOberver.Z1 fluorescence microscope (CarlZeiss, 
Germany). Six replicates were analyzed per experimental 
group for statistical analyses.
In vivo assessment of pro-angiogenic activity of 
SH-SY5Y and derived CIMVs
The animal study was approved by KFU ethics 
committee (protocol #2, date 05.05.2015) according 
with the rules adopted in KFU and Russian Federal 
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Laws. Angiogenic activity was examined using Wistar 
rats (Pushchino Laboratory, Russia) with 6 animals per 
experimental group. Matrigel (200 μl) containing 2x106 
SH-SY5Y cells (Group 1), 2x106 mitotically inactivated 
SHSY5Y cells (Group 2), SH-SY5Y-derived CIMVs 
at a concentration equivalent to 2×106 SH-SY5Y cells 
based on total protein concentration (4 mg/ml of total 
protein) (Group 3) and PBS (Group 4) was injected 
subcutaneously in the abdominal flanks. SH-SY5 cells 
and CIMVs were pre-labeled with the membrane dye 
DiO (Life Technologies, USA). Eight days after injection 
animals were sacrificed and matrigel plugs collected 
for examination. Matrigel plugs were frozen in liquid 
nitrogen and used to make 6 μm sections (NM560Cryo-
Star, Thermo Scientific, USA) for immunofluorescent 
analysis. Also, matrigel plug were paraffin embedded and 
stained with hematoxylin and eosin. Slides were examined 
using AxioOberver.Z1 (CarlZeiss, Germany) microscope 
with Axio Vision 4.8 software (CarlZeiss). For statistical 
analysis ten hematoxylin and eosin stained slides were 
analyzed per experimental group.
Statistical analysis
Statistical analysis was performed using Student’s 
t-test (Graphpad Software, San Diego, CA) with 
significance level p < 0.05.
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Cytochalasin B-induced membrane vesicles convey angiogenic 
activity of parental cells
SUPPLEMENTARY DATA
RESULTS
Influence of CIMVs method production on donor 
cell viability
We performed cell viability tests by Annexin V/PI 
and Calcein AM/7-AAD staining to evaluate (I) SH-SY5Y 
cells viability after 30 min of Cytochalasin B treatment 
and (II) SH-SY5Y cells viability after 30 sec of vortexing. 
Staining with Annexin V/ PI and Calcein AM/ 7-AAD 
indicates cell viability is not impaired following 30 min of 
Cytochalasin B treatment and after subsequent 30 sec of 
vortexing (Supplementary Figure 1, 2).
ΩInfluence of CIMVs on recipient cell viability
As cytochalasin B binds with actin filaments, trace 
amounts of cytochalasin B may be retained within CIMVs 
associated with actin fragments. We therefore evaluated 
HUVEC viability after addition of SH-SY5Y derived CIMVs 
using Calcein AM/ 7-AAD staining. SH-SY5Y derived 
CIMVs were added to the HUVEC culture (2x104 cells) at a 
concentration 60 μg/ml (Supplementary Figure 3).
Supplementary Figure 1: Annexin V/ PI staining of: (A) - control SH-SY5Y cells; (B) - SH-SY5Y cells after 30 min 
of Cytochalasin B treatment; (C) - SH-SY5Y cells after 30 min of Cytochalasin B treatment and subsequent 30 sec of 
vortexing.
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Supplementary Figure 2: Calcein AM/ 7-AAD staining of: (A) - control SH-SY5Y cells; (B) - SH-SY5Y cells after 30 
min of Cytochalasin B treatment; (C) - SH-SY5Y cells after 30 min of Cytochalasin B treatment and subsequent 30 
sec of vortexing.
Supplementary Figure 3: Calcein AM/ 7-AAD staining of: (A) - control HUVEC; (B) - HUVEC after 16 hours of 
CIMVs SHSY5Y addition.
